Live Chat Software

Leveraging Real World Data From Early Access Programmes

Leveraging Real World Data From Early Access Programmes

One of the key benefits of Early Access Programmes is that they allow companies to collect real world data from patients within the programme, which can help inform a product’s effectiveness and value proposition.

With insights from Tom Watson, Executive Vice President, Early Access Programmes, Bionical, in this article you will learn:

  • The benefits of gathering RWD during the testing phase
  • The preferred methods for RWD collection in patients with rare conditions 
  • The insights that RWD can provide to support expanded indication

Please note: That all fields marked with an asterisk (*) are required.